119 results
6-K
EX-3
BLRX
BioLineRx Ltd.
15 Aug 24
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate
7:06am
apoptosis (cell death) and inhibiting proliferation in various cancer cell models (multiple myeloma, non-Hodgkin’s lymphoma, leukemia, non-small-cell
6-K
EX-99.3
BLRX
BioLineRx Ltd.
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
apoptosis (cell death) and inhibiting proliferation in various cancer cell models (multiple myeloma, non-Hodgkin’s lymphoma, leukemia, non-small-cell
20-F/A
2023 FY
BLRX
BioLineRx Ltd.
26 Mar 24
Annual report (foreign) (amended)
4:57pm
of any of our contract manufacturers to maintain high manufacturing standards could result in injury or death of clinical trial participants or patients … demonstrated a direct anti-cancer effect by inducing apoptosis (cell death) and inhibiting proliferation in various cancer cell models (multiple myeloma, non
6-K
EX-99
BLRX
BioLineRx Ltd.
28 Sep 23
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination
7:11am
) is the most common type of pancreatic cancer and is expected to be the second leading cause of cancer-related death in the U.S. by 2023. Because
6-K
EX-99
nldvw4gxjb08d9ice4r
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
ys4n6w3r uxn9rlftcr
15 Sep 22
Current report (foreign)
8:39am
6-K
EX-1
0362d jmqp
4 Nov 21
BioLineRx Announces an Oral Presentation and Three
10:15am
6-K
EX-99
bhnn1z0a
21 Jan 21
Amended and Restated Underwriting Agreement
4:32pm
424B5
m13dmf2
21 Jan 21
Prospectus supplement for primary offering
4:31pm
424B5
2qs0pzg5wfgp emea
19 Jan 21
Prospectus supplement for primary offering
5:00pm
F-3
tn40hgxzi37 0sn
31 Dec 20
Shelf registration (foreign)
4:37pm
424B5
237qqdj0fewb2ht
31 Dec 20
Prospectus supplement for primary offering
4:31pm
6-K
EX-99
3pi8v9t5ep3a u4dll8t
16 Dec 20
Current report (foreign)
8:00am
424B5
culbfvypqexidthdfcx
13 Nov 20
Prospectus supplement for primary offering
4:31pm
424B5
fpsrtyt
25 Sep 20
Prospectus supplement for primary offering
4:30pm
424B5
s5jpc7a
3 Jun 20
Prospectus supplement for primary offering
8:33am